IBDEI20L ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34176,1,4,0)
 ;;=4^A60.04
 ;;^UTILITY(U,$J,358.3,34176,2)
 ;;=^5000356
 ;;^UTILITY(U,$J,358.3,34177,0)
 ;;=A60.01^^131^1682^32
 ;;^UTILITY(U,$J,358.3,34177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34177,1,3,0)
 ;;=3^Herpesviral Infection of Penis
 ;;^UTILITY(U,$J,358.3,34177,1,4,0)
 ;;=4^A60.01
 ;;^UTILITY(U,$J,358.3,34177,2)
 ;;=^5000353
 ;;^UTILITY(U,$J,358.3,34178,0)
 ;;=B00.1^^131^1682^33
 ;;^UTILITY(U,$J,358.3,34178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34178,1,3,0)
 ;;=3^Herpesviral Vesicular Dermatitis
 ;;^UTILITY(U,$J,358.3,34178,1,4,0)
 ;;=4^B00.1
 ;;^UTILITY(U,$J,358.3,34178,2)
 ;;=^5000468
 ;;^UTILITY(U,$J,358.3,34179,0)
 ;;=B97.89^^131^1682^89
 ;;^UTILITY(U,$J,358.3,34179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34179,1,3,0)
 ;;=3^Viral Agent Cause of Disease
 ;;^UTILITY(U,$J,358.3,34179,1,4,0)
 ;;=4^B97.89
 ;;^UTILITY(U,$J,358.3,34179,2)
 ;;=^5000879
 ;;^UTILITY(U,$J,358.3,34180,0)
 ;;=B97.10^^131^1682^21
 ;;^UTILITY(U,$J,358.3,34180,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34180,1,3,0)
 ;;=3^Enterovirus Cause of Disease
 ;;^UTILITY(U,$J,358.3,34180,1,4,0)
 ;;=4^B97.10
 ;;^UTILITY(U,$J,358.3,34180,2)
 ;;=^5000861
 ;;^UTILITY(U,$J,358.3,34181,0)
 ;;=B34.9^^131^1682^90
 ;;^UTILITY(U,$J,358.3,34181,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34181,1,3,0)
 ;;=3^Viral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,34181,1,4,0)
 ;;=4^B34.9
 ;;^UTILITY(U,$J,358.3,34181,2)
 ;;=^5000603
 ;;^UTILITY(U,$J,358.3,34182,0)
 ;;=A69.20^^131^1682^50
 ;;^UTILITY(U,$J,358.3,34182,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34182,1,3,0)
 ;;=3^Lyme Disease,Unspec
 ;;^UTILITY(U,$J,358.3,34182,1,4,0)
 ;;=4^A69.20
 ;;^UTILITY(U,$J,358.3,34182,2)
 ;;=^5000375
 ;;^UTILITY(U,$J,358.3,34183,0)
 ;;=A69.22^^131^1682^52
 ;;^UTILITY(U,$J,358.3,34183,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34183,1,3,0)
 ;;=3^Neurologic Disorders d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,34183,1,4,0)
 ;;=4^A69.22
 ;;^UTILITY(U,$J,358.3,34183,2)
 ;;=^5000377
 ;;^UTILITY(U,$J,358.3,34184,0)
 ;;=A69.21^^131^1682^51
 ;;^UTILITY(U,$J,358.3,34184,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34184,1,3,0)
 ;;=3^Meningitis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,34184,1,4,0)
 ;;=4^A69.21
 ;;^UTILITY(U,$J,358.3,34184,2)
 ;;=^5000376
 ;;^UTILITY(U,$J,358.3,34185,0)
 ;;=A69.29^^131^1682^18
 ;;^UTILITY(U,$J,358.3,34185,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34185,1,3,0)
 ;;=3^Conditions d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,34185,1,4,0)
 ;;=4^A69.29
 ;;^UTILITY(U,$J,358.3,34185,2)
 ;;=^5000379
 ;;^UTILITY(U,$J,358.3,34186,0)
 ;;=A69.23^^131^1682^5
 ;;^UTILITY(U,$J,358.3,34186,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34186,1,3,0)
 ;;=3^Arthritis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,34186,1,4,0)
 ;;=4^A69.23
 ;;^UTILITY(U,$J,358.3,34186,2)
 ;;=^5000378
 ;;^UTILITY(U,$J,358.3,34187,0)
 ;;=A51.0^^131^1682^29
 ;;^UTILITY(U,$J,358.3,34187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34187,1,3,0)
 ;;=3^Genital Syphilis,Primary
 ;;^UTILITY(U,$J,358.3,34187,1,4,0)
 ;;=4^A51.0
 ;;^UTILITY(U,$J,358.3,34187,2)
 ;;=^5000272
 ;;^UTILITY(U,$J,358.3,34188,0)
 ;;=A52.3^^131^1682^54
 ;;^UTILITY(U,$J,358.3,34188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34188,1,3,0)
 ;;=3^Neurosyphilis,Unspec
 ;;^UTILITY(U,$J,358.3,34188,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,34188,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,34189,0)
 ;;=A52.10^^131^1682^53
 ;;^UTILITY(U,$J,358.3,34189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34189,1,3,0)
 ;;=3^Neurosyphilis Symptomatic,Unspec
 ;;^UTILITY(U,$J,358.3,34189,1,4,0)
 ;;=4^A52.10
